ZolpiMist zolpidem tartrate regulatory update

FDA extended the review time for an NDA from NovaDel for ZolpiMist zolpidem oral spray for the short-term treatment of insomnia by 3 months to Dec. 19 from Sept. 21. The company said FDA needed additi...